Registry for patients with myeloproliferative neoplasms

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This registry collects clinical information and molecular results from patients diagnosed with various myeloproliferative neoplasms (MPNs) over time. It aims to establish a comprehensive database that enhances understanding of these rare hematological malignancies and improves patient outcomes by optimizing therapy assignments. Data will be gathered both prospectively and retrospectively, including clinical measures, treatment details, complications, and survival outcomes. The registry will serve as a valuable resource for future observational studies related to MPNs.

Why it matters

Who can join: the full rules

Inclusion Criteria:

Diagnosis of one of the following myeloproliferative neoplasms (MPNs):

* Atypical CML (aCML)
* Chronic eosinophilic leukemia-not otherwise specified (CEL, NOS),
* Chronic myelomonocytic leukemia (CMML)
* Chronic neutrophilic leukemia (CNL),
* Essential thrombocythemia (ET),
* Juvenile myelomonocytic leukemia (JMML),
* Mastocytosis, MPN unclassifiable
* MPN/MDS unclassifiable,
* Primary myelofibrosis (PMF),
* Post-essential thrombocythemia myelofibrosis (post-ET MF),
* Post-polycythemia vera MF (post-PV MF)
* Refractory anemia with ringed sideroblasts associated with marked thrombocytosis (RARS-T)

Exclusion Criteria:

* None

Where it's running

• Princess Margaret Cancer Centre
  Toronto, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Vikas Gupta, MD — University Health Network, Toronto
• Study coordinator: Vikas Gupta, MD
• Email: vikas.gupta@uhn.ca
• Phone: 416-946-4521

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Comparing ASTX727 with and without Iadademstat for advanced blood cancers

  This study is testing whether adding iadademstat to the ASTX727 treatment can help people with advanced blood cancers feel better and live longer compared to just using ASTX727 alone.

  Recruiting at 32 sites Phase 2 National Cancer Institute (NCI) · Irvine, California and 31 other locations · NCT06661915

• Characterizing Monocytes in Blood Disorders

  This study is trying to learn more about the role of certain blood cells called monocytes in patients with specific blood disorders to see how they might affect the disease and treatment options.

  Recruiting University Hospital, Angers · Angers, Maine et Loire and 2 other locations · NCT06361641

• Registry of Asian patients with myeloproliferative neoplasms

  This study is collecting information from Asian patients with myeloproliferative neoplasms to learn more about their condition and how different treatments work for them.

  Recruiting The University of Hong Kong · Hong Kong · NCT05882773

• Combining decitabine with ruxolitinib, fedratinib, or pacritinib for treating advanced myeloproliferative neoplasms

  This study is testing if combining decitabine with other medications can help patients with advanced blood cancers get ready for a stem cell transplant.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT04282187

• MPN PROGRESSion Registry — tracking symptoms, treatments, and disease progression in people with MPNs.

  Track long-term symptoms, treatments, and disease progression in adults with myeloproliferative neoplasms to see how these conditions evolve over time.

  Recruiting at 2 sites MPN Research Foundation · Chicago, Illinois and 1 other locations · NCT07362225

• Evaluating Peginterferon for treating Essential Thrombocythemia and Polycythemia Vera

  This study is testing if a weekly injection of Peginterferon can help people with Essential Thrombocythemia and Polycythemia Vera feel better and stay safe while using the treatment.

  Recruiting Tongji Hospital · Wuhan, Hubei · NCT06734637

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.